BiotechTube
Rokote Laboratories

Rokote Laboratories

Turku, Finland· Est.
rokote.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Rokote Laboratories is a private, pre-revenue biotech developing a novel intranasal vaccine platform. Its FINVAC technology uses an adenoviral vector backbone to create vaccines that target the nasal mucosa, aiming to block infection and transmission of respiratory viruses like SARS-CoV-2, influenza, and RSV. The company is currently in Phase I clinical development with its lead COVID-19 vaccine and is positioning its platform for pandemic preparedness and seasonal respiratory disease. Leadership combines expertise in virology, immunology, and clinical operations.

Infectious DiseasesRespiratory Diseases

Technology Platform

FINVAC - A universal intranasal vaccine platform based on a novel adenoviral vector backbone, designed to induce mucosal (IgA) and systemic (IgG) immunity by targeting the nasal mucosa. Features rapid adaptability, scalable RCA-free production, and a proprietary immunogenic buffer.

Opportunities

The clear unmet need for vaccines that block infection and transmission of respiratory viruses creates a large market for effective intranasal vaccines.
The platform's ease of administration offers a significant advantage for mass vaccination, pediatric use, and deployment in low-resource settings, aligning with global health equity goals.

Risk Factors

The company faces high clinical risk, as the ability to induce strong and durable mucosal immunity in humans is unproven.
As a small, pre-revenue private company, it is heavily dependent on securing external funding to continue operations and clinical trials.
It also operates in a competitive landscape with larger players developing similar intranasal candidates.

Competitive Landscape

Rokote competes in the emerging field of mucosal vaccines for respiratory diseases. Several companies and consortia worldwide are developing intranasal COVID-19 and influenza vaccines, including candidates from Codagenix, Bharat Biotech, and academic groups. Larger vaccine manufacturers like AstraZeneca and GSK are also active in this space, creating significant competition for funding, partnerships, and market share.

More companies in Biologics / Biosimilars →More companies in Finland →